Efatutazone hydrochloride

N/A

Report date: 2024/01/02 20:03:52
NME

Base Information

Drug NameEfatutazone hydrochloride
Drug Alias Nameefatutazona盐酸伊诺列宗盐酸依法他宗efatutazonumInolitazone hydrochloride +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPeroxisome proliferator-activated receptor γ agonists
TargetsPeroxisome proliferator-activated receptor γ
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungThyroid Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaUnited StatesUkraine +[17] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesDaiichi Sankyo Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesDaiichi Sankyo Co Ltd
Inactive CompaniesGeorgetown University
Active IndicationsThyroid NeoplasmsThyroid Carcinoma, AnaplasticLiposarcoma
Inactive IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksN/A